Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Poly( ADP ‐ribose) polymerase inhibition in pancreatic cancer

20 Dec 2020

Abstract excerpt

Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease with limited treatment options. Recently, the poly(ADP-ribose) polymerase inhibitor (PARPi) olaparib has been approved for maintenance therapy after successful platinum-based chemotherapy in patients with germline mutations in BRCA1 and BRCA2. Approval was based on the POLO study that has shown a significant improvement in progression-free survival for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA Repair Mechanisms
Share to Pancreatic and Hepatic Oncology Research
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33341987
DOI: 10.1002/gcc.22932

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Poly( ADP ‐ribose) polymerase inhibition in pancreatic cancerPMID 33341987Read ↗

PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applicationsSemantic proximity Read ↗

The role of PARP inhibitors in BRCA mutated pancreatic cancerSemantic proximity Read ↗

DNA Repair Dysfunction in Pancreatic Cancer: A Clinically Relevant Subtype for Drug Development.Semantic proximity Read ↗

Precision Medicine for BRCA/PALB2-Mutated Pancreatic Cancer and Emerging Strategies to Improve Therapeutic Responses to PARP InhibitionSemantic proximity Read ↗

BRCA mutations in pancreatic cancer and progress in their targeting.Semantic proximity Read ↗

DNA damage repair as a target in pancreatic cancer: state-of-the-art and future perspectivesSemantic proximity Read ↗

Olaparib Monotherapy for Previously Treated Pancreatic Cancer With DNA Damage Repair Genetic Alterations Other Than Germline BRCA VariantsSemantic proximity Read ↗

The Emerging Role of Poly(ADP-Ribose) Polymerase Inhibitors in Cancer TreatmentSemantic proximity Read ↗

An evaluation of olaparib for the treatment of pancreatic cancer.Semantic proximity Read ↗

Moving From Poly (ADP-Ribose) Polymerase Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer TherapySemantic proximity Read ↗

PARP-inhibitors in BRCA-associated pancreatic cancer.Semantic proximity Read ↗

Emerging strategies in BRCA-positive pancreatic cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.